



SPAFID
CONNECT

Informazione Regolamentata n. 20106-24-2022	Data/Ora Ricezione 28 Marzo 2022 17:47:03	Euronext Star Milan
---	---	---------------------

Societa' : PHARMANUTRA
Identificativo : 159238
Informazione
Regolamentata
Nome utilizzatore : PHARMANUTRAN04 - Roberto Lacorte
Tipologia : REGEM
Data/Ora Ricezione : 28 Marzo 2022 17:47:03
Data/Ora Inizio : 28 Marzo 2022 17:47:04
Diffusione presunta
Oggetto : PR - PHARMANUTRA Shareholders
meeting documents

Testo del comunicato

Vedi allegato.

PHARMANUTRA S.P.A.: FILING OF DOCUMENTS FOR THE SHAREHOLDERS' MEETING

Pisa, 28th March 2022 – **PharmaNutra S.p.A.** announces that the Directors' Reports on items 1 and 2 of the Shareholders' Meeting agenda are available in the registered office in Pisa, via delle Lenze 216/b, on the Company website www.pharmanutra.it in the section "Governance / Shareholders' Meeting", and in the authorised storage mechanism "eMarket Storage" on the website www.emarketstorage.com.

With reference to the Shareholders' Meeting for approval of the financial statements as at 31.12.2021, called for 27th April 2022 solely by remote communication means, please note that in order to vote Spafid S.p.A. has been appointed as Designated Representative. Delegation methods and forms can be found on the Company website in the section "Governance / Shareholders' Meeting".

PharmaNutra S.p.A.

Founded and led by the President Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra was established in 2003. It develops unique nutritional supplements and innovative nutritional devices, handling the entire production process, from proprietary raw materials to finished product. The efficacy of the products has been demonstrated with a wealth of scientific evidence, with 112 studies published involving more than 7000 subjects. The Group distributes and sells its products in Italy and abroad. In Italy, products are sold through a network of 140 Pharmaceutical Representatives serving doctors and also exclusively selling PharmaNutra products to pharmacies throughout Italy. Products are sold in over 50 countries abroad, through 34 partners selected from among the finest pharmaceutical companies. PharmaNutra leads the market in the production of iron-based nutritional supplements under the SiderAL® brand, where it boasts a number of important patents on Sucrosomial® technology. Over the years, the Group has developed a precise strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence.

PharmaNutra.it

For further information:

PharmaNutra S.p.A.

Via Delle Lenze, 216/b - 56122 Pisa

Tel. +39 050 7846500

investorrelation@PharmaNutra.it

Internal Press Office

press@calabughi.com

Press Office - Spriano Communication & Partners

Via Santa Radegonda, 16 - 20121 Milan

Tel. +39 02 83635708

Matteo Russo

mrusso@sprianocommunication.com

Cristina Tronconi

ctronconi@sprianocommunication.com

Fine Comunicato n.20106-24

Numero di Pagine: 4